The objective of this study was to define the frequency of fatal and nonfatal cardiovascular events attributable to atherosclerotic and nonatherosclerotic mechanisms , risk factors for these events , and the effects of cinacalcet , using adjudicated data collected during the EValuation of Cinacalcet HCl Therapy to Lower CardioVascular Events ( EVOLVE ) Trial .